manalikamdar@mana1981

HematoOncologist, eternal optimist, passionate about making every moment count

 Denver, CO
Joined October 2009
48 Photos and videos
Big dreams, bold ideas, and a proud sister cheering from the sidelines! ❤️ Congratulations to my brother @karan_martian on launching UnderLife.ai. Distributed SuperIntelligence in Multi-Agent Worlds piped.video/dlsCU2q_-5M?is=tqT4… via @YouTube

UnderLife: Distributed SuperIntelligence in Multi-Agent Worlds

UnderLife is a universe of endless worlds for AI agents. Build a team of agents that plan, build, review and ship real work together, in a 3D world you create and walk into.

underlife.ai
1
1
96
manalikamdar retweeted
Mazyar Shadman, MD MPH
@mshadman
Oct 29
Just published in @BloodAdvances! "CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma in the United States" Only ~15% of patients receive CAR T. We need to continue generating data, raising awareness, and improving access and utilization. ashpublications.org/bloodadv… Thanks to all the authors and collaborators at @bmsnews @lymphomaphilia @KrishPatelMD @LNastoupilMD @mana1981

CAR T-cell therapy referral patterns and utilization for relapsed/refractory large B-cell lymphoma...

Key Points. Real-world data showed that fewer than 2 in 10 patients with relapsed/refractory large B-cell lymphoma had access to CAR T-cell therapyLimited

ashpublications.org
1
12
28
1,737
Our T-cell lymphoma expert @CUAnschutz Dr. @BradHaverkos was interviewed on the @mghpetal #podcast about MRD monitoring in PTCL. #lymsm YouTube: piped.video/0OcU_FcZph4 Spotify: spotifycreators-web.app.link… Apple: podcasts.apple.com/us/podcas…

Molecular residual disease (MRD) in monitoring PTCL | PETAL Podcast...

In this episode of PETAL Podcast, hosted by Dr. Julia Zhang, we'll ...

youtube.com
PETAL Consortium@mghpetal
Oct 20
On the PETAL Podcast, host @yumengzhang2009 of @MoffittNews, discusses molecular residual disease monitoring in peripheral T-cell lymphoma with Dr. Brad Haverkos of @CUSystem. 🌸 Listen now: piped.video/0OcU_FcZph4 Also available on Spotify & Apple Podcasts.
3
5
395
Our @CUHematology program (@StevenBairMD @BradHaverkos @mana1981) just published a phase I trial of a homegrown CD19 CAR-T product which we manufacture on campus @CUAnschutz. #lymsm pubmed.ncbi.nlm.nih.gov/4224…
4
9
509
Looking forward to this year’s Lymphoma Research Foundation Educational Forum! Honored to co-chair the program and excited for two days of meaningful education, discussion, and updates for our lymphoma community. Hope you can join us! @lymphoma @WomenInLymphoma @CUCancerCenter
Lymphoma Research Foundation@lymphoma
Oct 2
The Educational Forum is a virtual two-day conference with important information about diagnosis and treatment, clinical trials, research advances and how to manage their disease. Date: Sat. Oct 10 – Sun. Oct 11 Find more info and register: bit.ly/4hdNA47
3
5
224
#IMS26 love this analogy by @YiLinMDPhD at the meeting 🤣 Some would say “Work hard, play hard” as we work as a field to cure myeloma… but I now prefer “Immune fitness & reconstitution” instead!! Plus shoutout to @HealthTree #WoMMen hike @GKaurMD et al!
4
15
1,760
Our @CULymphoma faculty Drs. @mana1981 & @majorajay were featured in this year's @CUDeptMedicine Annual Report. Lymphoma physicians represent! #lymsm
CU Anschutz Department of Medicine
@CUDeptMedicine
Sep 17
Our FY2026 Annual Report is officially live! 🎉 Rising Above: From Discovery to Care highlights the people, discoveries, and advances shaping the CU Anschutz Department of Medicine. Explore the stories and milestones from across our department. 💙 bit.ly/4y3GUwX
1
2
7
314
manalikamdar retweeted
Ajay Major, MD, MBA
@majorajay
Sep 18
TP53mut LBCL outcomes by tx modality @cduarte8490 @e_JHaem: - 183 pts, 78% DLBCL, 58% stage IV, 72% extranodal dz, 75% int/high IPI - overall: 2-yr PFS 53%, OS 76% - no benefit escalated 1L CIT - no OS difference by 2L/3L approach - DHL: better 2L PFS w/ CAR - 3L CAR/ASCT better PFS in DLBCL TP53 status alone not enough as biomarker for tx-selection in LBCL. TP53mut still can be cured. #lymsm doi.org/10.1111/ejh.70330
3
7
31
2,718
manalikamdar retweeted
VJHemOnc
@VJHemOnc
Sep 11
🎧 NEW podcast alert! In this week's episode, we're joined by Manali Kamdar (@mana1981), who discusses the use of BTK inhibitors for #NonHodgkinLymphoma in clinical practice. Dr Kamdar provides valuable advice on patient selection, adverse event management, response monitoring, and more.🩺🩸 Click here to listen now: 👉 ow.ly/3ASj50ZMx3O 👈 #Lymphoma #LYMsm #MantleCellLymphoma #DLBCL #HemOnc @CULymphoma @CUMedicalSchool
2
3
4
564
Our @CULymphoma lead Dr. @mana1981 just published a review on sequencing CD19-targeted therapies in LBCL. #lymsm sciencedirect.com/science/ar… cc @MediHumdani @heMEGirl_MD @gloria_iacoboni
2
7
353
Our @CULymphoma faculty Dr. @majorajay and @CUDeptMedicine chief resident Dr. @vpizzuti44 were featured in a @CUCancerCenter article about their recent study of quality of life after CAR T-cell therapy. #lymsm #mmsm
CU Anschutz Cancer Center@CUCancerCenter
Sep 2
In a new study, Ajay Major (@majorajay), MD, MBA, and Vincenzo Pizzuti, MD, MS, have tracked a group of blood cancer patients using multiple surveys over the course of two years to see how CAR T-cell therapy impacts their health-related quality of life: bit.ly/3UzIYxF
Vincenzo Pizzuti, MD, MS (left), and Ajay Major, MD, MBA, in the Research Quad at CU Anschutz.

ALT Vincenzo Pizzuti, MD, MS (left), and Ajay Major, MD, MBA, in the Research Quad at CU Anschutz.
2
4
686
Article link here: pubmed.ncbi.nlm.nih.gov/4261…
1
1
144
Our @CULymphoma lead Dr. @mana1981 and @CUInternalMed chief resident Dr. @vpizzuti44 contributed to a @BloodAdvances study on CAR-T vs ASCT in second-line PMBCL. pubmed.ncbi.nlm.nih.gov/4262… #lymsm
1
7
478
manalikamdar retweeted
Ajay Major, MD, MBA
@majorajay
Aug 17
Impressive cohort! Supports aiming for thiotepa-ASCT when eligible, while improving CAR-T/novel strategies esp for synchronous relapse. #lymsm #tcellrx ashpublications.org/blood/ar… 4/4
1
1
8
313
Our @CULymphoma faculty Drs. @majorajay & @StevenBairMD contributed to a publication @BloodAdvances about real-world outcomes of epcoritamab in R/R aNHL as part of the CUBIC Consortium. #lymsm ashpublications.org/bloodadv…
2
9
667
Our @CULymphoma lead Dr. @mana1981 was published @BloodPortfolio for a phase II trial of mosun/pola in patients with R/R MCL exposed to prior BTK inhibitors. #lymsm ashpublications.org/blood/ar…
2
9
489
manalikamdar retweeted
Ajay Major, MD, MBA
@majorajay
Aug 10
Mosun/pola in R/R MCL post BTKi @BloodPortfolio - 42 pts, 67% high Ki67, 48% TP53mut, 26% prior CAR - ORR 88% (CR 79%), post-CAR ORR 91%, TP53mut ORR 100% - mPFS 18.6 mos, mOS 20.7 mos - CRS 43% (all G1-2), ICANS 7% (all G1-2) - 5 (12%) G5 infection-related AEs (3 COVID, 1 WNV, 1 PNA) Great activity in heavily-pretx & very high-risk MCL. Severe infections are common theme with BsAb. #lymsm ashpublications.org/blood/ar…
9
22
1,224
Chief resident Dr. @vpizzuti44 @CUDeptMedicine and @CUHematology faculty Dr. @majorajay just published an analysis of longitudinal patient-reported outcomes over two years after receipt of CAR T-cell therapy, now in @BloodPortfolio. #lymsm #mmsm sciencedirect.com/science/ar…
3
6
644
Our junior @CULymphoma faculty Dr. @cduarte8490 was interviewed by @JADPRO about CAR T-cell therapy for CNS lymphomas. #lymsm #tcellrx resources.advancedpractition…
2
7
253
manalikamdar retweeted
IDEOlogy Health
@IDEOlogyHealth
Jul 17
Dr. Manali Kamdar (@mana1981) breaks down best practices and the critical impact of when to utilize CAR-T therapy in patients with large B-cell lymphoma. Short, sharp insights from a leading expert that can directly shape patient outcomes. Sign up for free to watch this Sound Bite and get an entry to our monthly iPad Giveaway drawing! ow.ly/1Ugg50Zmttr #CART #LBCL #Lymphoma #HemOnc #PrecisionMedicine
3
5
313
Load more